Value proposition

AI-guided neurostimulation for memory loss

Nia Therapeutics is developing a precision neurostimulation therapy for the treatment of memory loss. More than 27M Americans are living with memory loss due to traumatic brain injury, degenerative disease and aging, and there are currently no effective therapies available. Our core technology was developed with funding from the Dept. of Defense, and it utilizes artificial intelligence to personalize each patient's therapy based upon their unique patterns of brain activity. Our therapeutic strategy has been validated in multiple clinical publications, and we have demonstrated the functionality of our commercial prototype in a large animal model. Our first clinical target is memory loss due to traumatic brain injury, a large market that will provide a launchpad into the larger mild cognitive impairment and Alzheimer's markets.